Baseline Productions

Baseline Productions Documents

Documents

82

Ticker

BSSP

ISIN

US0702491079

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Baseline Productions SEC Filings

Type
Report
Date
SEC STAFF ACTIONSEC STAFF ACTION-Formular7/6/2022
1-A1-A-Formular9/27/2021
15-12G15-12G-Formular8/16/2017
SC 13G/ABeneficial ownership report2/16/2017
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/3/2016
SC 13GSC 13G-Formular5/10/2016
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/25/2016
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/14/2016
10-Q/A10-Q/A-Formular1/13/2016
10-QQuartalsbericht11/23/2015
NT 10-QNT 10-Q-Formular11/17/2015
SC 13GSC 13G-Formular11/10/2015
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/3/2015
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/21/2015
10-QQuartalsbericht8/17/2015
NT 10-QNT 10-Q-Formular8/14/2015
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/7/2015
SC 14F1SC 14F1-Formular8/6/2015
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben7/28/2015
10-QQuartalsbericht5/15/2015
10-KJahresbericht3/31/2015
8-K/A8-K/A-Formular12/15/2014
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/11/2014
10-QQuartalsbericht11/13/2014
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/12/2014
10-Q/A10-Q/A-Formular10/7/2014
10-Q/A10-Q/A-Formular10/7/2014
10-K/A10-K/A-Formular10/7/2014
10-Q/A10-Q/A-Formular10/7/2014
10-QQuartalsbericht8/14/2014
DEF 14CDEF 14C-Formular6/27/2014
PRE 14CPRE 14C-Formular6/17/2014
10-QQuartalsbericht5/20/2014
NT 10-QNT 10-Q-Formular5/14/2014
10-KJahresbericht4/15/2014
NTN 10KNTN 10K-Formular4/4/2014
UPLOADUPLOAD-Formular3/14/2014
UPLOADUPLOAD-Formular3/6/2014
CORRESPCORRESP-Formular3/3/2014
10-K/A10-K/A-Formular2/27/2014
10-QQuartalsbericht11/19/2013
NT 10-QNT 10-Q-Formular11/14/2013
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/5/2013
10-QQuartalsbericht8/12/2013
10-Q/A10-Q/A-Formular6/21/2013
10-QQuartalsbericht6/20/2013
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/19/2013
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/13/2013
NT 10-QNT 10-Q-Formular5/15/2013
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/14/2013
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/3/2013
10-KJahresbericht4/1/2013
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/14/2013
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/10/2012
33-Formular12/10/2012
10-QQuartalsbericht11/6/2012
10-QQuartalsbericht8/10/2012
10-QQuartalsbericht5/14/2012
10-KJahresbericht3/30/2012
33-Formular3/30/2012
33-Formular3/20/2012
10-QQuartalsbericht11/10/2011
10-Q/A10-Q/A-Formular9/21/2011
8-A12G8-A12G-Formular9/12/2011
10-QQuartalsbericht8/22/2011
NT 10-Q/ANT 10-Q/A-Formular8/16/2011
NT 10-QNT 10-Q-Formular8/16/2011
424B2424B2-Formular7/26/2011
EFFECTEFFECT-Formular7/25/2011
CORRESPCORRESP-Formular7/21/2011
S-1/AS-1/A-Formular7/6/2011
UPLOADUPLOAD-Formular7/1/2011
S-1/AS-1/A-Formular6/22/2011
UPLOADUPLOAD-Formular5/4/2011
S-1/AS-1/A-Formular4/25/2011
UPLOADUPLOAD-Formular4/8/2011
S-1/AS-1/A-Formular3/25/2011
S-1/AS-1/A-Formular2/2/2011
UPLOADUPLOAD-Formular12/22/2010
S-1/AS-1/A-Formular12/8/2010
UPLOADUPLOAD-Formular11/3/2010
S-1S-1-Formular10/6/2010

Baseline Productions Documents 2026

This page contains all official documents and SEC filings for Baseline Productions stock (BSSP, ISIN: US0702491079). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 82 documents are available. Data is updated regularly to provide investors with a complete overview of Baseline Productions's regulatory filings.

Baseline Productions Stock analysis

Baseline Productions Baseline Productions Inc develops mobile based hardware and software based products. The company focuses on commercialization of its proteins for cancer and infectious disease treatments. Its Irreversible Pepsin Fraction (IPF) technology activates the immune system to fight autoimmune diseases. IPF binds to T-cells and triggers Th1 responses that eliminate infected cells. The firm's lead compound is an IPF suspension for autoimmune disease treatment including cancer, cirrhosis, and Hepatitis C. The product IMMUNE-THERAPEUTIC PROTEIN (ITP) is a therapeutic protein derived from porcine pepsin, which is irreversible, modified, and fractionated to IPF sequence. The company sells its IPF platform technology and ITP product to healthcare providers and pharmaceutical companies. Healthcare providers use IPF for immune system activation in autoimmune disease treatment. Pharmaceutical companies purchase ITP for development into therapeutic applications. The target segments include medical institutions treating autoimmune conditions and drug manufacturers seeking novel protein-based therapies. ITP is specifically indicated for cancer, cirrhosis, and Hepatitis C treatment. Baseline Productions generates revenue through licensing IPF technology and selling ITP therapeutic protein. The IPF platform is sold as a technology solution to partners in the healthcare sector. ITP is marketed as a therapeutic product for direct sale to medical facilities. The company's primary customers are healthcare institutions and pharmaceutical firms interested in immune system-based treatments for autoimmune diseases and infectious conditions.